Calosyn Pharma

About:

Calosyn Pharma focuses on developing innovative treatments for osteoarthritis.

Top Investors: MB Venture Partners, BVM Capital

Description:

Calosyn Pharma focuses on developing innovative treatments for osteoarthritis. Its product, CAL-05CR, is a sustained-release injectable therapy that combines verapamil with a biodegradable delivery system. This treatment is designed to provide long-lasting pain relief and reduce inflammation by targeting the underlying causes of osteoarthritis, such as abnormal calcium ion channel signaling.

Total Funding Amount:

$3.32M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Shreveport, Louisiana, United States

Founded Date:

2007-09-01

Contact Email:

rgrimes(AT)calosyn.com

Founders:

David Waddell, Dr. Reid Grimes, PhD.

Number of Employees:

1-10

Last Funding Date:

2022-12-22

IPO Status:

Private

Industries: